PharmaLinea Secures Technical and Quality Award at HNC Shanghai

At the 2026 edition of the Healthplex Expo, Natural & Nutraceutical Products China (HNC) trade show, private label manufacturer PharmaLinea received the Leading Enterprise for Quality & Tech Breakthrough Award.¹ Introduced for the first time at this year's Shanghai event, the award highlights PharmaLinea’s ongoing focus on quality and innovation while underscoring the expanding commercial potential of the Chinese nutraceutical sector for international manufacturers and brands.

What Is Driving Consumer Demand and Product Growth in China?

As stated by PharmaLinea in a press release, data from Innova Market Insights emphasizes China's strong position within the global dietary supplement industry. As reported in 2025, more than 25% of supplement consumers in China increased their overall intake, and 80% buy supplement products at least once per month.² Furthermore, China leads the Asian region in new dietary supplement product introductions, posting a 4% compound annual growth rate (CAGR) over the past five years.

"China has become an increasingly relevant market to follow for nutraceutical companies," commented Matevž Ambrožič, Marketing Director at PharmaLinea. "We see growing consumer interest in nutrition and wellbeing, strong engagement at industry events, and increasing opportunities to connect with local partners."

This market momentum is driving increased participation at major regional trade exhibitions, the company also highlights. Alongside HNC Shanghai, events like the China International Import Expo (CIIE) have become key venues for international brands—including Bayer, Haleon, Reckitt, GNC, Johnson & Johnson, and Sanofi—to launch new products and connect with regional commercial partners. PharmaLinea has responded to these trends by expanding its presence, with plans to exhibit at both HNC and CIIE moving forward.

How Are Global Trade Dynamics Impacting Sourcing and Manufacturing Choices?

According to PharmaLinea, recent shifts in global trade dynamics are altering how companies structure their supply chains. During recent trade shows, including Vitafoods Europe and HNC Shanghai, the company noted an uptick in inquiries regarding European manufacturing capabilities. International brands are actively exploring manufacturing alternatives to diversify their sourcing strategies in response to evolving international trade conditions.

This shift presents a strategic opening for European contract manufacturers, the company states. In competitive global arenas like China, European production maintains a strong reputation for rigorous quality controls, making the "Made in EU" designation a valuable market differentiator. Consequently, European suppliers can provide high-quality manufacturing alongside supply chain security for expanding brands.

What Regulatory Barriers and Strategic Steps Form the Path to Market Entry?

Despite the market's potential, entry for foreign manufacturers and brands requires managing complex regulatory frameworks, the company highlights. Navigating compliance procedures—such as securing specific product registrations and obtaining General Administration of Customs of China (GACC) approvals—remains a substantial operational hurdle.

"The market that requires patience, local understanding, and sustained effort," added Ambrožič. "Success is built over time through relationships, regulatory compliance, and a willingness to invest in understanding the market."

For dietary supplement manufacturers, the evolving landscape in China may represent a dual reality: substantial consumer demand and a need for supply chain diversification, balanced by strict regulatory barriers that demand a long-term strategic investment.

What are PharmaLinea’s Previous Expansions?

In late 2025, PharmaLinea announced its acquisition by French industrial group ANJAC Health & Beauty.³ By joining ANJAC’s ecosystem of complementary entities, the private label developer gained access to extensive infrastructure, cross-sector expertise, and advanced R&D resources.

“This partnership opens an era of extraordinary opportunity,” Anton Oražem, CEO of PharmaLinea had stated about the acquisition. “It will give wings to PharmaLinea’s story, while at the same time complementing and completing the offering that ANJAC provides to its partners worldwide.”

References

1. PharmaLinea Ltd. PharmaLinea highlights growing opportunities in China's nutraceutical market following HNC recognition. July 2026. Accessed July 7, 2026. Press release provided via email.
2. Innova Market Insights. Supplement Market Trends in China. June 2, 2025. Accessed July 7, 2026. https://www.innovamarketinsights.com/reports/supplement-market-trends-in-china/
3. Colli M. PharmaLinea joins ANJAC Health & Beauty through acquisition. November 12, 2025. Accessed July 7, 2026. https://www.nutritionaloutlook.com/view/pharmalinea-joins-anjac-health-beauty-through-acquisition